Lotus Pharmaceuticals, Inc.
LTUS
https://www.otcmarkets.com/stock/LTUS/quote
Lotus Pharmaceuticals, Inc.
controls and operates Liang Fang Pharmaceutical, Ltd. (“Liang Fang”) and Enze Jiashi Pharmaceutical, Ltd. (“Enze”), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and Enze (“Lotus East”) undertake the development, production, marketing and distribution of pharmaceutical products. The Company believes Lotus East has some of the most advanced pharmaceutical production equipment in China and its manufacturing facilities meet national Good Manufacturing Practices. The Company distributes its own portfolio of drugs and pharmaceutical products produced by other manufacturers in the PRC through an extensive national distribution network. Lotus owns ten pharmacies in Beijing through which it directly sells over 5,000 western drugs, Traditional Chinese Medicines and medical equipment items.
Business Description
Lotus Pharmaceuticals is both a licensed manufacturer and distributor of pharmaceutical products in the People's Republic of China. Its principal manufactured products are prescription medicines, including Valsartan, used to reduce hypertension and high blood pressure; Brimonidine Tartrate, a glaucoma treatment; Levofloxacin Lactate, an intravenous anti-bacterial; and Nicergoline, an anti-dementia drug. The company also distributes products on behalf of third party pharmaceutical manufacturers directly through its distribution network.
Lotus Pharmaceutical
Former Names
S.E. ASIA TRADING COMPANY, INC. (until 2006-11-28)
Stock
OTCBB:LTUS
Standard Industry
Classification
Pharmaceutical preparations
Address
16 Cheng Zhuang Road, Beijing, F4 100071
Phone
LTUS Security Details
Share Structure
| | Market Value1 | $183,589 | a/o May 17, 2017 |
| | Authorized Shares | Not Available |
| | Outstanding Shares | 27,816,455 | a/o Nov 10, 2011 |
List of Employees on Linkedin
https://www.linkedin.com/company-beta/3994893/
https://www.linkedin.com/search/results/people/?facetCurrentCompany=%5B%223994893%22%5D
Jefferson Wang
General Manager/ Country Head of Lotus under Alvogen Group
Jefferson Wang currently is working for Lotus Pharmaceuticals as General Manager/Country Head under Alvogen Group.
The annual sales of Lotus is over 200 million USD in 2016. Jefferson has had 20 years of experience in various positions across China, US and Taiwan. He started his career as PSR, then was promoted to various positions in Marketing, SFE, Training, Marketing Excellence, Business Management, Strategic Marketing and BU Management. Major achievements were awarded such as James E. Burke, the highest global marketing award at J&J. He has the right skills, expertise, experience, passion and connections to grow the business in various companies including MSD, BMS, Janssen and J&J. Mobile: +886 909994992 Email: Jefferson.wang@alvogen.com
https://www.linkedin.com/in/jefferson-wang-8ba59a35/
NEWS and Development
Alvogen Partially Acquires Lotus Pharma For US$200 Million
Lotus Pharmaceutical has signed a deal with US-based drug maker Alvogen Group Inc, allowing Alvogen to acquire 60 percent of its shares.
Asian Scientist Newsroom | January 3, 2014 | Pharma AsianScientist (Jan. 3, 2014) -
Lotus Pharmaceutical Co., a company that makes and distributes oral and vaccine medications, has signed a deal with US-based drug maker Alvogen Group Inc, allowing Alvogen to acquire 60 percent of its shares for US$200 million. “Lotus Pharmaceutical can achieve greater market access through this cooperation, and both companies can have a stronger portfolio because we have a different product-mix,” said Charles Lin, chairman of Lotus Pharmaceutical Co. The Taiwan-based firm plans to sell shares to Alvogen through a private placement after the deal is approved by its shareholders. Lotus Pharmaceutical plans to use the proceeds to finance R&D and set up international retail chains in the US, according to the Taipei Times. Lotus Pharmaceutical will make drugs for Alvogen, and they will be sold in Asia. The companies are to also cooperate on strategies for the markets in China, India, Thailand, Myanmar, Singapore, Malaysia and South Korea. Alvogen will also assist Lotus Pharmaceutical to apply for drug permits and sell its products in the US. “Our costs for making drugs for the Asian market are lower than Alvogen’s, and we will start by making Alvogen’s oral medicine for the treatment of cancer,” said Lotus Pharmaceutical’s chief finance officer Ben Chung. Read more from Asian Scientist Magazine at:
http://www.asianscientist.com/2014/01/pharma/alvogen-partially-acquires-lotus-pharma-creates-cancer-treatment-drugs-2014/
Alvogen and Lotus Pharmaceuticals Merge Asian Operations to Create Compelling Platform for International Growth
- Alvogen to become 67% shareholder in Lotus; Lotus to use funds to acquire Alvogen’s Asian operation
Combined regional group will have increased regional market reach and a broadened product portfolio
Exclusive marketing rights for two high-value biopharmaceuticals for selective APAC markets are under negotiations between the parties
Robert Wessman, Chairman & CEO of Alvogen
January 16, 2014 10:58 AM Eastern Standard Time
PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the multinational pharmaceuticals company, agreed in December 2013 to become the majority shareholder in Taiwanese Lotus Pharmaceuticals (“Lotus”) through a private placement of newly issued shares, acquiring up to 151 million shares in the company. The total transaction value will be approximately US$200 million (approx. NTD 6 billion). As a results of the transaction, Alvogen´s shareholding will be approximately 67% in Lotus.
“This partnership represents an exciting development for Alvogen and Lotus, both of which will benefit from increased scale, a larger portfolio and broader geographic reach. The new Group will represent compelling value for our shareholders, and creates a strong platform for growth in Asia Pacific and internationally.”
Following the above transaction, Alvogen and Lotus today announce that Lotus is using the proceeds of the share issue to acquire several of Alvogen’s businesses in Asia. Exclusive distribution rights for two high-value biopharmaceuticals for selective Asian markets are under negotiations between the parties. Transaction value is approximately US$ 200 million.
The combination of Alvogen’s strong geographic coverage in the US, Central and Eastern Europe and Asia with Lotus’ strategically important foothold in the Taiwanese market and its growing US product pipeline is expected to generate significant opportunities to drive revenue growth, margin enhancement and create further value for the two companies. Both Alvogen and Lotus will benefit from the increased scale, portfolio and geographic reach.
Key Benefits of the Transaction
Combined with Alvogen‘s October 2012 purchase of the South Korean company, Kunwha Pharmaceuticals, the partnership with Lotus will significantly strengthen Alvogen’s position in the key Asia Pacific region with enhanced reach into Taiwan and China and a new market presence in Japan.
Alvogen will gain access to high potency and cytotoxic oral formulation capacity through Lotus’ FDA approved manufacturing facility, as well as securing broad experience in marketing and distribution in the region. Together, the companies will have manufacturing and product development capabilities in North America, Taiwan, South Korea, and Romania.
Through Alvogen, Lotus will gain a sales and marketing network in more than 30 countries that will enhance its export opportunities as well as provide access to Alvogen’s global pipeline for the Taiwanese market. Alvogen and Lotus will collaborate in the important US market, by developing more difficult to produce generic products. Commenting on the transaction, Mr. Robert Wessman, Chairman and CEO of Alvogen, said: "The proposed transactions between Alvogen and Lotus represent a highly exciting opportunity for both companies. These transactions will create a significantly enlarged group, which will enhance its market presence in Asia, with a broad product portfolio and international market reach. Alvogen’s investment in Lotus offers compelling value for Lotus’ shareholders, providing the group with significant opportunities to drive revenue growth, enhance margins and create further value for the two companies.”
Charles Lin, Chairman of Lotus, added "This partnership represents an exciting development for Alvogen and Lotus, both of which will benefit from increased scale, a larger portfolio and broader geographic reach. The new Group will represent compelling value for our shareholders, and creates a strong platform for growth in Asia Pacific and internationally.”
Both transactions are subject to shareholder and regulatory approvals, and closing is expected in the second quarter 2014.
About Alvogen
Alvogen is a multinational, privately owned pharmaceuticals company focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of: oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 2000 employees. North America is Alvogen’s single largest market and other key markets include: South-Korea, Romania, Bulgaria, Hungary, Russia and China. Visit: www.alvogen.com
About Lotus Pharmaceuticals
Lotus Pharmaceuticals is a specialty pharmaceuticals company in Taiwan with FDA-inspected manufacturing facilities. The company’s product portfolio emphasizes difficult to formulate CNS (central nervous system) and oral oncology drugs. The company currently has 278 employees, with headquarters in Tapei, Taiwan.
http://www.lotuspharm.com/investors/investor-news
Visit: http://www.lotuspharm.com.tw/
Taiwanese market
[TPEx] 1795 LOTUS PHARM
http://mis.twse.com.tw/stock/fibest.jsp?stock=1795
The Taiwanese pharmaceutical market is currently valued at around US$6 billion and is expected to grow by about 5% over the next five years. The share of the generic market by volume is around 40%. Taiwan is a hospital-based market, with hospitals representing some 78% of the market, followed by retail drugstores and GP/Clinics. The Taiwanese economy is closely linked to China and, through recently signed agreements including the Economic Cooperation Framework Agreement (ECFA), the Taiwanese pharmaceutical industry will be able to profit from wider access to the Chinese market.
Note to editors:
For more information on Alvogen and to download logo or images of senior management, please visit the Alvogen website, www.alvogen.com.
Contacts
Google News
https://www.google.com/finance/company_news?q=OTCMKTS%3ALTUS&ei=x7UbWbDUMtGie83EhIgK
Fiscal Year 2010 Financial Highlights:
Revenues for the 2010 fiscal year increased by 28.7% year-over-year to $72.7 million, up from $56.5 million in 2009.
Wholesale revenue was $51.4 million, or 70.7% of total revenues.
Retail revenues were $21.3 million, or 29.3% of total revenues.
Gross profit for the year was $39.8 million, an increase of 26.6% compared to $31.4 million in 2009. Gross margin was 54.7% and 55.6% in 2010 and 2009, respectively.
Adjusted* net income increased 16.7% to $21.2 million, compared to $18.2 million in 2009
GAAP net income decreased 12.2% year-over-year to $14.4 million, compared to $16.4 million in the previous year
Earnings per diluted share were $0.54 for the year, compared with diluted EPS of $0.66 achieved in the previous year
Management Commentary for 2010 Results:
Mr. Zhongyi Liu, Chairman and CEO of Lotus, stated, "We continued to expand our business in 2010 and saw especially strong growth of 83% in our retail sales segment. We entered the market for direct sales to over-the-counter drugstores in Beijing in 2010 and have already experienced tremendous success, serving more than 1,000 OTC drugstores in addition to our own 10 stores. We expect this channel to continue being a major sales growth driver in the coming year. Construction of our Beijing facility continues to progress, and we anticipate significant efficiency improvements and additional capacity for growth once we move into the new building."
Mr. Liu continued, "We plan to focus our capital expenditures in the foreseeable future on the completion of ourBeijing facility and our core business in Beijing; as a result, we recognized a one-time, non-cash impairment loss for construction expenditures on our property in Inner Mongolia in 2010. Lotus has a well-established nationwide sales and distribution network, strong product development capabilities, and access to capital. Due to the trends of consolidation and increasing regulatory oversight in China's pharmaceuticals industry, we believe these characteristics position Lotus to emerge as an industry leader."
AUDITOR: FRIEDMAN LLP: (85 years experience)
Friedman LLP has been serving the accounting, tax and business consulting needs of public and private companies since 1924. Our industry-focused practice features concentrated areas of expertise and understanding of the economic environment. We have the ability to be innovative in our approach, act quickly in our decision-making and be flexible in our delivery of services. Our clients benefit from hands-on contact with our partners, cutting-edge technical expertise and our understanding of their industry and their business. Our clients have the advantage of working with a mid-size accounting firm that combines the staff and resources of a large firm with a philosophy of personal responsibility for our clients. Please also visit our practice and service areas to learn more about our firm. (source: http://www.friedmanllp.com/firm_overview.php)
See link below for most recent RedChip Conference with LTUS Presentation from Xing Shen:
http://www.redchip.com/visibility/video/displayClientVideoflashconf.asp?symbol=LTUS&root=VCFEB2011&fileloc=LTUS_VCFEB2011_pres&descr=RedChip%20Virtual%20Conference%20VI)
